

# M Fernanda Amary

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5605852/publications.pdf>

Version: 2024-02-01

44  
papers

4,411  
citations

201674

27  
h-index

276875

41  
g-index

44  
all docs

44  
docs citations

44  
times ranked

6043  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. <i>Journal of Pathology</i> , 2011, 224, 334-343.	4.5	834
2	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. <i>Nature Genetics</i> , 2013, 45, 1479-1482.	21.4	667
3	Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of <i>IDH1</i> and <i>IDH2</i> . <i>Nature Genetics</i> , 2011, 43, 1262-1265.	21.4	368
4	Recurrent <i>PTPRB</i> and <i>PLCG1</i> mutations in angiosarcoma. <i>Nature Genetics</i> , 2014, 46, 376-379.	21.4	269
5	Frequent mutation of the major cartilage collagen gene <i>COL2A1</i> in chondrosarcoma. <i>Nature Genetics</i> , 2013, 45, 923-926.	21.4	180
6	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. <i>Nature Communications</i> , 2017, 8, 15936.	12.8	179
7	H3F3A (Histone 3.3) G34W Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1059-1068.	3.7	153
8	Meta-analysis of <i>IDH</i> -mutant cancers identifies <i>EBF1</i> as an interaction partner for <i>TET2</i> . <i>Nature Communications</i> , 2013, 4, 2166.	12.8	152
9	Diagnostic value of <i>H3F3A</i> mutations in giant cell tumour of bone compared to osteoclast-rich mimics. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 113-123.	3.0	135
10	The driver landscape of sporadic chordoma. <i>Nature Communications</i> , 2017, 8, 890.	12.8	115
11	A common single-nucleotide variant in <i>T</i> is strongly associated with chordoma. <i>Nature Genetics</i> , 2012, 44, 1185-1187.	21.4	112
12	The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. <i>Histopathology</i> , 2016, 69, 121-127.	2.9	109
13	Recurrent rearrangements of <i>FOS</i> and <i>FOSB</i> define osteoblastoma. <i>Nature Communications</i> , 2018, 9, 2150.	12.8	106
14	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. <i>Cancer Cell</i> , 2019, 35, 441-456.e8.	16.8	82
15	Detection of <i>USP6</i> gene rearrangement in nodular fasciitis: an important diagnostic tool. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 97-98.	2.8	80
16	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. <i>Journal of Pathology</i> , 2016, 239, 320-334.	4.5	73
17	In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. <i>Clinical Cancer Research</i> , 2017, 23, 7426-7434.	7.0	73
18	Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by <i>FN1</i> gene rearrangement. <i>Modern Pathology</i> , 2019, 32, 1762-1771.	5.5	67

#	ARTICLE	IF	CITATIONS
19	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 88-99.	2.8	67
20	<i>IDH1</i> mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. <i>Histopathology</i> , 2012, 60, 363-365.	2.9	60
21	Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2014, 3, 980-987.	2.8	57
22	FOS Expression in Osteoid Osteoma and Osteoblastoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1661-1667.	3.7	50
23	Activating mutations in the MAPK kinase pathway define nonossifying fibroma of bone. <i>Journal of Pathology</i> , 2019, 248, 116-122.	4.5	49
24	Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. <i>Skeletal Radiology</i> , 2013, 42, 947-957.	2.0	48
25	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. <i>Modern Pathology</i> , 2015, 28, 1336-1342.	5.5	47
26	Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 217-222.	2.8	37
27	PRDM10-rearranged Soft Tissue Tumor. <i>American Journal of Surgical Pathology</i> , 2019, 43, 504-513.	3.7	35
28	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. <i>Cancer Medicine</i> , 2017, 6, 2194-2202.	2.8	26
29	DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the "DKFZ Sarcoma Classifier"™. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 350-360.	3.0	25
30	The Chemical Form of Metal Species Released from Corroded Taper Junctions of Hip Implants: Synchrotron Analysis of Patient Tissue. <i>Scientific Reports</i> , 2017, 7, 10952.	3.3	24
31	Drivers underpinning the malignant transformation of giant cell tumour of bone. <i>Journal of Pathology</i> , 2020, 252, 433-440.	4.5	21
32	H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. <i>Journal of Pathology</i> , 2020, 252, 151-164.	4.5	20
33	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 297-307.	3.0	20
34	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. <i>Journal of Clinical Pathology</i> , 2018, 71, 388-394.	2.0	14
35	Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. <i>Modern Pathology</i> , 2022, 35, 767-776.	5.5	14
36	MYC amplifications are common events in childhood osteosarcoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 425-431.	3.0	12

#	ARTICLE	IF	CITATIONS
37	Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 106-112.	3.0	9
38	Ossifying Fibroma of Non-odontogenic Origin: A Fibro-osseous Lesion in the Craniofacial Skeleton to be (Re-)considered. <i>Head and Neck Pathology</i> , 2022, 16, 257-267.	2.6	9
39	Mutational analysis of high-grade spindle cell sarcoma of the femur in Mazabraud's syndrome. <i>Skeletal Radiology</i> , 2019, 48, 151-157.	2.0	5
40	EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum. <i>Skeletal Radiology</i> , 2021, 50, 445-450.	2.0	4
41	Benign Bone-Forming Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 549-565.	1.7	4
42	Gout-mimicking sarcoma recurrence at a prosthesis bone interface remote from any joint. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 605-607.	1.8	0
43	Molecular testing of sarcomas. <i>Diagnostic Histopathology</i> , 2017, 23, 431-441.	0.4	0
44	Precocious pseudo-puberty in a 2-year-old girl, presenting with bilateral ovarian enlargement and progressing to unilateral juvenile granulosa cell tumour. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2021, .	0.9	0